Insider Purchases: Inside the Buy
Tag: insurance stocks
🦅 Erie Indemnity (ERIE): The Hidden Fee Castle Behind an 11-Day Short Squeeze Setup
Erie Indemnity isn't a traditional insurer. It collects fees rather than assuming most underwriting risk, creating one of the most unique business models in financial services. After a rare $1.4 million insider purchase, a 59% decline from all-time highs, and nearly 12 days-to-cover short interest, investors may want another look at this Dividend Aristocrat.
🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock
Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.
💼 Willis Towers Watson (WTW): The Quiet Compounder Smart Money Keeps Buying
WTW isn’t flashy—but when the CEO buys the dip and institutions own nearly everything, it’s worth a closer look. A quiet compounder trading at a rare discount.
The “WTW” Strategy Scorecard: Why the Smart Money Is Huddled Here
Willis Towers Watson isn’t a hype stock—it’s a fortress. With insider buying, 100%+ institutional ownership, surging margins, and massive buybacks, WTW is quietly becoming one of the smartest “sleep-well” investments of 2026.
CEO and COO Buy Shares of RLI — Exceptionally Run Insurer, but Not Without Storm Clouds
RLI Corp is exceptionally well run, with insider buying and 30 years of underwriting profits — but forward valuation and catastrophe risk argue for patience, not haste.
Insiders Purchase Shares of Goosehead Insurance — Should You Buy, Duck, or Just Take a Gander?
Insiders are loading up on Goosehead Insurance shares — and institutions can’t get enough. With strong growth but real risks, is this goose ready to fly… or cooked? Here’s the fun, smart breakdown. 🪿📈🔥
Executive Chairman Adds To His Already Huge Stake in Ryan Specialty Holdings. Should You Follow His Lead?
Executive Chairman Patrick Ryan just added $14M to his already massive stake in Ryan Specialty Holdings. With strong revenue growth and heavy institutional backing, is this insurance play worth your portfolio — or is it still too pricey?